AbbVie blood cancer therapy cuts disease progression risk by 60% in late-stage trial
AbbVie (ABBV) said its experimental blood cancer therapy etentamig met the primary endpoints of a late-stage trial, reducing the risk of disease progression or death by 60 per cent compared with standard treatments and delivering an…